Journal Article (Review Article)

DZNE-2026-00700

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.

Bernhardt, A. M.Extern* ; Höglinger, G. U.DZNE* ; Palleis, C. (Last author)DZNE*

2026
Frontiers Research Foundation Lausanne

This record in other databases:    

Please use a persistent id in citations: doi:10.3389/fnagi.2026.1801615

Abstract: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are primary tauopathies defined by aggregation of four-repeat (4R) tau, yet early in vivo diagnosis remains limited by the dissociation between clinical phenotype and molecular pathology. Clinical presentations are heterogeneous, evolve over time, and frequently overlap with Alzheimer's disease, synucleinopathies, and mixed pathologies, particularly in corticobasal syndrome. As a result, clinical criteria provide structured phenotypic classification but have constrained specificity in early disease. This review synthesizes current evidence relevant to early diagnostic stratification in 4R tauopathies, integrating clinical criteria, supportive biomarkers of neurodegeneration, and emerging tau-directed molecular tools. The probabilistic value and limitations of contemporary criteria frameworks are discussed alongside the role of structural and functional imaging, dopaminergic imaging, and fluid markers as indicators of disease intensity and progression rather than molecular specificity. Advances in tau positron emission tomography and tau seed amplification assays are reviewed as biologically grounded approaches that directly interrogate aggregated and seed-competent tau species, with growing evidence for their potential contribution to individual-level stratification. Collectively, the literature supports a layered diagnostic approach in which clinical phenotype, supportive biomarkers, and tau-directed molecular measures are integrated to refine attribution of 4R tau pathology in vivo, a prerequisite for mechanism-based therapeutic development.

Keyword(s): Parkinson’s disease ; biomarkers ; corticobasal degeneration ; neurodegenaration ; progressive supra nuclear palsy ; synuclein alpha (SNCA) ; tauopathies

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; ; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---